Retatrutide phase 3 obesity trial results are out, and it's safe to say that this is the next generation of obesity medicine: - 28.3% bodyweight lost on 12mg over 80 weeks (70.3 lbs) - 30.3% at 104 weeks in higher-BMI patients (85 lbs) - 45.3% of patients hit 30%+ weight loss - 65.3% dropped below the obesity BMI threshold - notable drops in blood pressure, triglycerides, cholesterol & inflammation - no cardiac or liver signals For those of you who are new to peptides, the reason retatrutide works better than semaglutide and tirzepatide is its mechanism. Semaglutide hits one hormone, tirzepatide hits two, but retatrutide hits three: GLP-1, GIP, and glucagon. Glucagon increases the amount of energy your body burns at rest so you eat less and burn more at the same time. Retatrutide is the drug that has the potential to end the obesity pandemic.
